What is 3billion?
Based in Seoul, 3billion operates at the intersection of bioinformatics and clinical diagnostics. The company specializes in developing high-throughput gene sequencing technologies designed to identify rare genetic disorders with unprecedented accuracy. By integrating artificial intelligence with genomic data, 3billion provides healthcare providers with actionable insights, effectively shortening the diagnostic odyssey for patients suffering from rare conditions. Its market position is bolstered by a robust intellectual property portfolio and a commitment to fostering a sustainable healthcare ecosystem through technological innovation.
How much funding has 3billion raised?
3billion has raised a total of $291M across 3 funding rounds:
Series A
$268M
Series B
$10M
Series C
$13M
Series A (2018): $268M with participation from Korea Development Bank, JW Assets, and The Wells Investment
Series B (2019): $10M led by Korea Development Bank, JW Assets, and The Wells Investment
Series C (2021): $13M supported by Aventures Investment, The Wells Investment, Yuanta Investment, Korea Investment & Securities, Magna Investment, Kakao Investment, and JW Assets
Key Investors in 3billion
Korea Development Bank
A state-owned policy development bank in South Korea that provides essential capital and management support to foster the growth of strategic industrial projects.
The Wells Investment
A South Korean venture capital and private equity firm focused on sustainable prosperity by providing capital and expertise to growth-stage companies in bio-healthcare and deep tech.
Yuanta Investment
A venture firm committed to maximizing value for portfolio companies through methodical screening, rigorous due diligence, and strategic management consulting.
What's next for 3billion?
With the recent capital injection, 3billion is expected to accelerate its research and development initiatives, focusing on expanding its diagnostic database and enhancing the scalability of its screening services. The company is likely to prioritize international market penetration, seeking to establish strategic partnerships with global healthcare institutions and diagnostic laboratories. As it transitions from a growth-stage venture to a more mature enterprise, 3billion will likely focus on operational efficiency and the commercialization of its diagnostic pipeline to solidify its leadership in the rare disease screening market.
See full 3billion company page
